ADMA Biologics Inc (ADMA)

Return on equity (ROE)

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Net income (ttm)	US$ in thousands	68,132	34,788	-3,645	-28,240	-22,827	-40,292	-47,686	-65,905	-70,322	-73,135	-78,275	-71,647	-74,406	-73,610	-74,883	-75,748	-66,901	-61,422	-54,456	-48,279
Total stockholders’ equity	US$ in thousands	231,890	188,269	153,706	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336	26,193
ROE		29.38%	18.48%	-2.37%	-20.89%	-15.07%	-27.45%	-32.74%	-43.37%	-70.05%	-63.93%	-61.67%	-50.75%	-72.39%	-65.96%	-66.56%	-85.83%	-93.73%	-79.89%	-56.53%	-184.32%

September 30, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $68,132K ÷ $231,890K
= 29.38%

ADMA Biologics Inc's return on equity (ROE) has varied significantly over the periods indicated in the table. The ROE was positive and relatively high in the most recent quarter, standing at 29.38%. This suggests that the company generated a strong return for its shareholders during this period.

However, it is important to note that the ROE fluctuated widely in previous quarters, with negative values recorded in several instances. The ROE was notably low in earlier periods, reaching as low as -184.32% in December 2019, indicating substantial losses relative to shareholders' equity.

The improvement in ROE in the latest quarter may indicate positive developments in the company's financial performance and efficiency in the utilization of shareholders' equity. It would be essential to monitor future ROE trends to assess the sustainability of this positive performance and the effectiveness of the company's strategies in enhancing shareholder value.